Citi adjusts MedTech outlook: Bullish on Haemonetics, bearish on Tandem Diabetes
Investing.com -- Citi analysts have taken action on two U.S. MedTech names, upgrading Haemonetics (NYSE:HAE) to Buy from Neutral, while downgrading Tandem Diabetes Care (NASDAQ:TNDM) to Sell/High Risk from Neutral/High Risk, citing diverging prospects in the second half of 2025.